Windtree Therapeutics (NASDAQ:WINT) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) Critical Contrast

Windtree Therapeutics (NASDAQ:WINT) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.

Profitability

This table compares Windtree Therapeutics and Brainstorm Cell Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Windtree Therapeutics	N/A	-275.06%	-56.28%
Brainstorm Cell Therapeutics	N/A	N/A	-376.40%

Institutional and Insider Ownership

29.3% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 0.5% of Windtree Therapeutics shares are owned by insiders. Comparatively, 5.5% of Brainstorm Cell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Windtree Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Windtree Therapeutics and Brainstorm Cell Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Windtree Therapeutics	0	1	0	0	2.00
Brainstorm Cell Therapeutics	0	1	0	0	2.00

Valuation & Earnings

This table compares Windtree Therapeutics and Brainstorm Cell Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Windtree Therapeutics	N/A	N/A	-$20.29 million	($143.89)	-0.03
Brainstorm Cell Therapeutics	N/A	N/A	-$17.19 million	($0.41)	-0.93

Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

About Windtree Therapeutics

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitorfor the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has collaboration with Chang Gung University; collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.